Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)

OBJECTIVES: To confirm the effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab in patients with rheumatoid arthritis (RA) in a setting close to real-life medical care in Germany. METHODS: A multicentre open-label phase IIIb study was undertaken. Patients with active RA with...

Descripción completa

Detalles Bibliográficos
Autores principales: Burmester, Gerd R, Feist, E, Kellner, H, Braun, J, Iking-Konert, C, Rubbert-Roth, A
Formato: Texto
Lenguaje:English
Publicado: BMJ Group 2010
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070275/
https://www.ncbi.nlm.nih.gov/pubmed/21187298
http://dx.doi.org/10.1136/ard.2010.139725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070275/
https://www.ncbi.nlm.nih.gov/pubmed/21187298
http://dx.doi.org/10.1136/ard.2010.139725

Ejemplares similares